5248W-12: ENLiST Registry

Evaluating Nulojix Long-Term Safety in Transplant

Type of Study
Kidney/Dialysis - Kidney Transplant
Location
Transplant Program
Short Description

Purpose: To describe how Nulojix (belatacept) is used and to determine how often Post-Transplant Lymphoproliferative Disorder (PTLD), Central Nervous System (CNS) PTLD and Progressive Multifocal Leukoencephalopathy (PML), rare and serious complications of transplant treatment, occur in patients taking Nulojix (belatacept) in a real-world setting.

Status
OPEN
Principal Investigator
Nelson Goes, M.D.
Eligibility Notes
  • Adult kidney transplant recipient (age ≥18 years at time of transplant)
  • Kidney-only transplant recipient
  • Positive EBV serostatus EBV serostatus negative or unknown included per the investigator discretion
  • Received first dose of Nulojix (Belatacept) within ≤ 14 days of renal transplant
  • Received first dose of Nulojix (Belatacept) as part of normal clinical care (i.e. not as part of a clinical trial)
  • Must not have received Nulojix (Belatacept) for non-kidney transplants
Contact Name
Julie Wallick
Phone
(206) 215-3986
Email
Julie.Wallick@swedish.org